Anticoagulation Fails to Prevent Cognitive Decline in AF Patients
Originally Published 1 year ago — by Medscape
A trial investigating the use of the anticoagulant rivaroxaban to prevent cognitive decline in atrial fibrillation (AF) patients was halted due to lack of efficacy. The BRAIN-AF study found no significant difference in cognitive decline between patients taking rivaroxaban and those on placebo, despite a high overall rate of cognitive decline. The study, which involved low-risk AF patients, suggests that other mechanisms beyond microemboli may contribute to AF-related cognitive decline, warranting further research.